MetaCap

Alterity Therapeutics (ATHE) vs BriaCell Therapeutics (BCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 56.7% versus a loss of 61.7%. Over five years, ATHE leads with a -85.4% price change compared with -97.0% for BCTX. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%BCTX-61.75%
+74%+1%-72%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%BCTX-97.12%
+18%-43%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus BCTX key metrics
MetricATHEBCTX
Share price$1.52$3.06
Market cap$29.02M$26.72M
1-day change-8.16%-3.32%
YTD return-50.65%-56.96%
1-year return-56.70%-61.75%
5-year return-85.38%-97.00%
EPS (TTM)$-0.90$-6.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-34.90M
52-week high$5.89$13.09
52-week low$1.52$2.60
Distance from 52-week high-74.19%-76.62%
Analyst consensusnone—
Avg. price target upside+771.71%—
Average volume89.63K250.81K
Shares outstanding19.09M8.73M
Employees11—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

ATHE vs BCTX FAQ

Which is bigger, Alterity Therapeutics or BriaCell Therapeutics?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, ATHE or BCTX?

ATHE returned -56.70% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and BriaCell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons